NAMSW · NewAmsterdam Pharma Co N.V. · Documents
$8.25
-1.00 (-10.81%)
At close · Oct 26
Return incl. dividend (before tax)
Q3 2025 earnings call transcript
Market Cap
$2.45B
Shares
119.54M
Volume · Oct 26
241
Avg daily vol (3M)
2621
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | NewAmsterdam Pharma Company N.V. announced dosing the first participant in SPINOZA, a Phase 2b trial evaluating obicetrapib in approximately 400 participants with preclinical Alzheimer’s disease. | 2026-09-29 | — | |
| 8-K | NewAmsterdam Pharma Company N.V. received European Commission marketing authorization for Ubeslo® and Evlarco®, the first worldwide obicetrapib approval. It will receive tiered double-digit royalties and up to €833 million in milestones. | 2026-09-21 | — | |
| 8-K | — | 2026-08-14 | 2026-08-10 | |
| 8-K/A | — | 2026-08-14 | 2026-07-16 | |
| 10-Q | — | 2026-08-05 | 2026-06-30 | |
| 8-K | — | 2026-08-05 | — | |
| 8-K | — | 2026-07-24 | — | |
| 8-K | — | 2026-07-22 | 2026-07-16 | |
| Investor Event Transcript | — | 2026-06-09 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-06-03 | 2026-06-30 | |
| 8-K | — | 2026-06-03 | 2026-06-02 | |
| Investor Event Transcript | — | 2026-05-13 | 2026-06-30 | |
| 8-K | — | 2026-05-07 | — | |
| 10-Q | — | 2026-05-07 | 2026-03-31 | |
| DEF 14A | — | 2026-05-06 | — | |
| ARS | — | 2026-05-06 | 2025-12-31 | |
| 8-K | — | 2026-04-24 | 2026-04-20 | |
| PRE 14A | — | 2026-04-20 | — | |
| 8-K | — | 2026-03-02 | — | |
| 10-K | — | 2026-02-18 | 2025-12-31 | |
| 8-K | — | 2026-02-18 | — | |
| 8-K | — | 2026-01-09 | — | |
| 8-K | — | 2025-11-05 | — | |
| 10-Q | — | 2025-11-05 | 2025-09-30 | |
| 8-K | — | 2025-09-02 | — | |
| 8-K | — | 2025-08-18 | — | |
| 8-K | — | 2025-08-15 | 2025-08-12 | |
| 10-Q | — | 2025-08-06 | 2025-06-30 | |
| 8-K | — | 2025-08-06 | — | |
| 8-K | — | 2025-07-30 | — | |
| 8-K | — | 2025-07-11 | — | |
| 8-K | — | 2025-06-11 | — | |
| 8-K | — | 2025-06-09 | — | |
| 8-K | — | 2025-06-06 | 2025-06-04 | |
| ARS | — | 2025-05-08 | 2024-12-31 | |
| 8-K | — | 2025-05-08 | — | |
| DEF 14A | — | 2025-05-08 | 2025-06-04 | |
| 10-Q | — | 2025-05-08 | 2025-03-31 | |
| 8-K | — | 2025-05-07 | — | |
| PRE 14A | — | 2025-04-28 | 2025-06-04 | |
| 8-K | — | 2025-04-17 | 2025-04-15 | |
| S-3 | — | 2025-02-28 | — | |
| 8-K | — | 2025-02-26 | — | |
| 10-K | — | 2025-02-26 | 2024-12-31 | |
| 8-K | — | 2025-01-10 | — | |
| 8-K | — | 2024-12-13 | 2024-12-11 | |
| 8-K | — | 2024-12-10 | — | |
| 8-K | — | 2024-12-10 | — | |
| 8-K | — | 2024-11-20 | — | |
| 8-K | — | 2024-11-18 | — |
Showing 1–50 of 111 filings